ESR1 and breast carcinoma: To date, studies have shown that ERα36 is overexpressed in breast cancer stem cells18–21, ER-positive and -negative human breast carcinomas22, endometrial carcinomas23 and gastric carcinomas24, which is associated with malignancy, invasion, metastasis, drug resistance and poor prognosis of these tumors.